Ask the Spin-off Pro's
27.05.15 - 18:00 Uhr
Creating your own company is a tough business. After five years, only one half of all Swiss startups continue to exist. Yet when a startup has spun out of ETH, 90% of all businesses survive past their first five years. What is it that they do differently?
How to start your own Spin-Off
Use this opportunity to grill our panel of five ETH entrepreneurs from early to mid-stage Spin-Offs on the nitty-gritty details of their success. After the registration you can create and vote on questions in Google Moderator for the panel discussion.
Date & Location
27. May 2015, 18:00
ETH Main Building, Dozentenfoyer
Swiss-based u-blox is a fabless semiconductor provider of positioning and wireless communication chips, modules and software for the automotive, industrial and consumer markets. u-blox has offices and R&D centers located all over the world.
u-blox products are used by over 3500 customer for a wide range of applications, including many for IoT. More than 10‘000 types of devices rely on our products, and more than 50‘000‘000 people and machines utilize our technology.
Daniel Ammann has served as Executive Vice President (R&D Software) of u-blox Holding AG from 2007 to 2012. He has been a member of the Board of u-blox AG from 1997 to 2003 and acted as Executive Vice President R&D Software from 1997 to 2012. He acts as Executive Director Positioning Product Development since 2012. He holds a degree in electrical engineering from the Swiss Federal Institute of Technology Zurich (ETH).
Sadik Hafizovic is co-founder and CEO of Zurich Instrument AG. Zurich Instruments develops and sells high-precision electronic instrumentation for research and industry. Together with Flavio Heer and Beat Hofstetter he spunoff Zurich Instruments from ETH Zurich in 2008. Since its incorporation, the company has grown from 3 to more than 30 people and has taken technology leadership in the field of Lock-in Amplifiers. 90% of Zurich Instruments’ revenue is generated abroad while production is almost exclusively in Switzerland.
Dr. Alexander Ilic - Chairman and CTO
Dr. Alexander Ilic is founder, CTO, and Chairman of the Board. Alex is Dacuda’s visionary and the driving force that brought Dacuda together.
Alex has an interdisciplinary background. He holds a PhD in Management, Technology, and Economics from ETH Zurich and a MSc in Computer Science from TU Munich. He also studied at the Massachusetts Institute of Technology. Alex received several grants including a scholarship of the Swiss National Science Foundation in 2009. Alex has two years of industry experience as head of a business unit and five years as software engineer. He also worked as independent consultant for companies in the SAP domain to optimize their internationalization and growth strategies.
Dacuda is a Swiss software company offering a unique content capturing technology based on real-time image processing. Dacuda's patented, proprietary SLAM Scan technology enables fast data entry of text and images, instant editing, as well as easy sharing of contents. It can be implemented into any device that embeds a camera. The world’s first Scanner Mouse and leading smartphone based e-banking solutions are driven by Dacuda’s technology.
Dacuda licenses its technology to leading hardware and software vendors.
Lukas is CTO and co-founder of investiere. He has an academic background in computer science (ETH Zurich and ENST in Paris) and is an experienced management consultant in the financial services industry.
investiere is one of Europe’s leading online investment platforms. Since 2010, over 25 startups have used investiere to raise funds (over 12 million Swiss francs in total) from private investors with relevant industry expertise and networks. The +6'000 strong investiere community identifies investment opportunities which are then reviewed by experts and the investiere-team. Investiere-investors participate in financing rounds alongside institutional investors and prominent business angels.
Inositec, Pioneer Fellowship Program
Dr. Mattias Ivarsson is currently a Pioneer Fellow at ETH Zurich. He carried out his undergraduate studies at EPFL, Cornell University and ETH Zurich in biomedical engineering before moving on to do a PhD in pharmaceutical sciences at the latter institution. Parallel to his studies, Mattias gained professional experience through work at McKinsey, Siemens Management Consulting and the World Health Organisation. His business idea, Inositec, will focus on the development of a new therapy against a common healthcare-associated infection, Clostridium difficile infection.